Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GNMarie-Sophie Meuleman, Sophie Chauvet, Claire Dossier et al.|Clinical Journal of the American Society of Nephrology|2023Cited by 25
Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric studyChristophe Passot, Philippe Gatault, Rébecca Sberro‐Soussan et al.|British Journal of Clinical Pharmacology|2020Cited by 15
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised IndividualsChristoph D. Spinner, Gkikas Magiorkinis, Samira Bell et al.|Advances in Therapy|2024Cited by 10
Eculizumab dose tapering should take into account the nonlinearity of its pharmacokineticsOlivier Le Tilly, David Ternant, Philippe Gatault et al.|British Journal of Clinical Pharmacology|2024Cited by 4